Reporter brief
Sirolimus in Older Adults- Randomized Trial Assessing the Improvement in Phenotypic/Functional Biomarkers of Aging
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy or safety data are presented, making this a protocol or preliminary description rather than a completed trial report
- The absence of results precludes any conclusion about whether rapamycin actually affects aging biomarkers or clinical outcomes in older adults
- The stated hypothesis about mTOR inhibition slowing aging is based on animal studies and theory, not demonstrated clinical evidence from this trial
Study design and sample
Rct; Human.
Older adults
- Design
- Rct
- Sample
- —
- Journal
- NOT_REPORTED
- Published
- Jun 25, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.